Chronic obstructive pulmonary disease (COPD) is among the most common breathing conditions. It's the result of damaged lung ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments for people with type 2 diabetes and COPD. Image credit: Visual Vic/Getty Images. Researchers estimate the number of people ...

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This in-depth analysis shows that the Global Asthma and COPD Drugs Market, valued at ...

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Roflumilast is used to reduce COPD exacerbations in patients with severe chronic bronchitis. The US market for the drug was valued at approximately $32 million as of June 2024, according to IQVIA ...

Please provide your email address to receive an email when new articles are posted on . Significantly more patients from the injurious fall group had all but one of the studied prescription ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...